Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324896 | 0.85 | SLC18A3 (0.41) | ROCK2HSD11B1SLC18A3DRD2DRD4 | |
| SCHEMBL22324860 | 0.85 | DRD2 (0.44) | SLC18A3DRD2DRD3SIGMAR1 | |
| SCHEMBL22324798 | 0.85 | SLC18A3 (0.41) | DHFRIP6K1ROCK2HSD11B1SLC18A3 | |
| SCHEMBL22324937 | 0.85 | FAAH (0.42) | ROCK2MLYCDDRD2DRD3 | |
| SCHEMBL22324795 | 0.83 | TRPV6 (0.50) | DHFRROCK2DRD2DRD4DRD3 | |
| SCHEMBL22324803 | 0.83 | ROCK2 (0.49) | ROCK2MLYCD | |
| SCHEMBL22324762 | 0.83 | NR3C1 (0.43) | HSD11B1DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL22324845 | 0.82 | GRM2 (0.44) | MAPT | |
| SCHEMBL22324868 | 0.82 | DRD2 (0.49) | DRD2SIGMAR1MAPT | |
| SCHEMBL22324884 | 0.80 | MAPT (0.48) | DHFRDRD2DRD4DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | DHFR 436/4885IP6K1 2171/4885ROCK2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.